Literature DB >> 21387451

Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.

Xingchen Wu1, Pirkko-Liisa Kellokumpu-Lehtinen, Hannu Pertovaara, Pasi Korkola, Seppo Soimakallio, Hannu Eskola, Prasun Dastidar.   

Abstract

To determine the feasibility of diffusion-weighted MRI (DWI) in the evaluation of the early chemotherapeutic response in patients with aggressive non-Hodgkin's lymphoma (NHL), eight patients with histologically proven diffuse large B-cell lymphoma were imaged by MRI, including DWI, and positron emission tomography/computed tomography (PET/CT) before treatment (E1), and after 1 week (E2) and two cycles (E3) of chemotherapy. In all patients, whole-body screening using T(1) - and T(2) -weighted images in the coronal plane was performed. To quantitatively evaluate the chemotherapeutic response, axial images including DWI were acquired. Apparent diffusion coefficient (ADC) maps were reconstructed, and the ADC value of the tumor was measured. In addition, the tumor volume was estimated on axial T(2) -weighted images. The maximum standardized uptake value (SUV(max) ) and active tumor volume were measured on fused PET/CT images. Lymphomas showed high signal intensity on DW images and low signal intensity on ADC maps, except for necrotic foci. The mean pre-therapy ADC was 0.71 × 10(-3) mm(2) /s; it increased by 77% at E2 (p < 0.05) and 24% more at E3 (insignificant); the total increase was 106% (p < 0.05). The mean tumor volume by MRI was 276 mL at baseline; it decreased by 58% at E2 (p < 0.05) and 65% more at E3 (p < 0.05), giving a total decrease of 84% (p < 0.05). All the imaged pre-therapy tumors were strongly positive on PET/CT, with a mean SUV(max) of 20. The SUV(max) decreased by 60% at E2 (p < 0.05) and 59% more at E3 (p < 0.05), giving a total decrease of 83% (p < 0.05). The active tumor burden decreased by 66% at E2 (p < 0.05). At baseline, both central and peripheral tumor ADC values correlated inversely with SUV(max) (p < 0.05), and also correlated inversely with active tumor burden on PET/CT and with tumor volume on MRI at E2 (p < 0.05). In conclusion, the results of DWI in combination with whole-body MRI were comparable with those of integrated PET/CT.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21387451     DOI: 10.1002/nbm.1689

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  30 in total

1.  Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma Treatment Response.

Authors:  W-Y Huang; J-B Wen; G Wu; B Yin; J-J Li; D-Y Geng
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-07       Impact factor: 3.825

2.  Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.

Authors:  Xiao-Li Song; Heoung Keun Kang; Gwang Woo Jeong; Kyu Youn Ahn; Yong Yeon Jeong; Yang Joon Kang; Hye Jung Cho; Chung Man Moon
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

3.  Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI.

Authors:  Ashok J Theruvath; Florian Siedek; Anne M Muehe; Jordi Garcia-Diaz; Julian Kirchner; Ole Martin; Michael P Link; Sheri Spunt; Allison Pribnow; Jarrett Rosenberg; Ken Herrmann; Sergios Gatidis; Jürgen F Schäfer; Michael Moseley; Lale Umutlu; Heike E Daldrup-Link
Journal:  Radiology       Date:  2020-05-05       Impact factor: 11.105

Review 4.  Diffusion-weighted imaging in pediatric body magnetic resonance imaging.

Authors:  Govind B Chavhan; Pablo Caro-Dominguez
Journal:  Pediatr Radiol       Date:  2016-05-26

5.  Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.

Authors:  Asim Afaq; Francesco Fraioli; Harbir Sidhu; Simon Wan; Shonit Punwani; Shih-Hsin Chen; Oguz Akin; David Linch; Kirit Ardeshna; Jonathan Lambert; Kenneth Miles; Ashley Groves; Irfan Kayani
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

6.  Can diffusion-weighted whole-body MRI replace contrast-enhanced CT for initial staging of Hodgkin lymphoma in children and adolescents?

Authors:  Rodrigo Regacini; Andrea Puchnick; Flavio Augusto Vercillo Luisi; Henrique Manoel Lederman
Journal:  Pediatr Radiol       Date:  2018-01-23

7.  Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.

Authors:  Julian Kirchner; Cornelius Deuschl; Bernd Schweiger; Ken Herrmann; Michael Forsting; Christian Buchbender; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-22       Impact factor: 9.236

8.  Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.

Authors:  Antoinette de Jong; Thomas C Kwee; John M H de Klerk; Judit A Adam; Bart de Keizer; Rob Fijnheer; Marie José Kersten; Inge Ludwig; Yvonne W S Jauw; Josée M Zijlstra; Indra C Pieters-Van den Bos; Jaap Stoker; Otto S Hoekstra; Rutger A J Nievelstein
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-04-25

9.  Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen.

Authors:  Marius E Mayerhoefer; Ahmed Ba-Ssalamah; Michael Weber; Markus Mitterhauser; Harald Eidherr; Wolfgang Wadsak; Markus Raderer; Siegfried Trattnig; Andreas Herneth; Georgios Karanikas
Journal:  Eur Radiol       Date:  2013-03-08       Impact factor: 5.315

Review 10.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.